April 28, 2017
1 min read
Save
Nicox reports first quarter highlights
Nicox reported it had cash, cash equivalents and financial instruments totaling 25 million as of March 31 compared with 28.9 million as of Dec. 31, 2016, according to a press release.
No revenues were recorded for the first quarter.
Operationally, the company’s resubmitted new drug application for Vyzulta (latanoprostene bunod ophthalmic solution 0.024%) received a PDUFA date of Aug. 24, and its resubmitted NDA for Zerviate (cetirizine ophthalmic solution 0.24%) has a PDUFA date of Sept. 8.